Objectives Anxiety is associated with elevated levels of the inflammatory cytokine interleukin-6 (IL-6) and an increased risk for diseases with an inflammatory aetiology. In cancer, higher levels of IL-6 have been associated with increased expression of the epigenetic enzymes DNMT1 and Enhancer of Zeste Homolog 2 (EZH2). However, the relationship between IL-6 and DNA methyltransferases (DNMTs) and EZH2 expression has not previously been examined in anxious individuals.
Anxiety is associated with higher levels of global DNA methylation and altered expression of epigenetic and interleukin-6 genes Objectives Anxiety is associated with elevated levels of the inflammatory cytokine interleukin-6 (IL-6) and an increased risk for diseases with an inflammatory aetiology. In cancer, higher levels of IL-6 have been associated with increased expression of the epigenetic enzymes DNMT1 and Enhancer of Zeste Homolog 2 (EZH2). However, the relationship between IL-6 and DNA methyltransferases (DNMTs) and EZH2 expression has not previously been examined in anxious individuals.
Methods Global DNA methylation levels were measured using the Methylflash Methylated DNA Quantification Kit and gene expression levels of the DNMT and EZH2 genes in anxious (n = 25) and nonanxious individuals (n = 22) were compared using quantitative real-time PCR. Specifically, we investigated whether global DNA methylation or aberrant expression of these genes was correlated with IL-6 mRNA and protein serum levels in anxious individuals.
Results Anxious participants had significantly higher levels of global DNA methylation compared with controls (P = 0.001). There were no differences in the mean mRNA expression levels of the DNMT1/3A/3B, EZH2 and IL-6 genes in anxious individuals compared with controls. However, the expression of DNMT1/3A, EZH2 and IL-6 genes increases with increasing Hospital Anxiety and Depression Scale-Anxiety scores in the anxious cohort only.
Interestingly, IL-6 gene expression was correlated strongly with DNMT1/3A/3B and EZH2 expression, highlighting a potential relationship between IL-6 and important epigenetic regulatory enzymes.
Conclusion This study provides novel insight into the relationship between anxiety, epigenetics and IL-6. Moreover, our findings support the hypothesis that changes in DNA methylation profiles may contribute to the biology of anxiety. Psychiatr Genet 25:71-78 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Anxiety is associated with an increased risk for many diseases with an inflammatory aetiology including cardiovascular and autoimmune diseases and some forms of cancer (Kiecolt-Glaser et al., 2002) . However, the mechanisms by which anxiety might promote these diseases are not well understood. Prolonged upregulation of proinflammatory cytokines is thought to contribute to chronic inflammation in anxious individuals, which may mediate their increased risk for inflammation-related diseases (Kiecolt-Glaser et al., 2002) . Previously, our group has shown that anxious individuals have significantly higher serum levels of the systemic proinflammatory cytokine, interleukin-6 (IL-6), compared with nonanxious individuals (O'Donovan et al., 2010) . In turn, high levels of IL-6 increase the risk for cardiovascular and autoimmune diseases as well as cancer (Kiecolt-Glaser et al., 2003) .
Epigenetics, defined as the mechanisms that initiate and maintain heritable patterns of gene expression without altering the sequence of the genome (Holliday, 1987) , may play an important role in the pathology of psychiatric disorders (Poulter et al., 2008; Zhubi et al., 2009 ) and inflammatory-related diseases, including cancer (Baylin, 2005; Wilson, 2008) . The epigenetic mark DNA methylation involves the addition of methyl groups to the 5′-position of cytosine rings [5-methylcytosine (5-mC)] at CpG dinucleotides. DNA methylation is orchestrated by several DNA methyltransferases (DNMTs -DNMT1, DNMT3A, DNMT3B, DNMT3L) in combination with polycomb group proteins (Viré et al., 2006) . DNMT1 is a maintenance enzyme that binds methyl groups to hemimethylated DNA during DNA replication (Smith et al., 1992) . DNMT3A and 3B are de-novo DNMT enzymes that establish methylation patterns during embryonic development and genomic imprinting (Chédin, 2011) . DNMT3L interacts with and enhances DNMT3A/3B methyltransferase activity in vivo (Chen et al., 2005) . Interestingly, the polycomb group protein, Enhancer of Zeste Homolog 2 (EZH2), is known to interact with DNMTs and is required for DNA methylation of EZH2-target promoters (Viré et al., 2006) . Thus, DNMTs and EZH2 are essential epigenetic regulatory enzymes involved in the heritable repression of gene activity.
Higher levels of IL-6 are associated with increased expression and activity of DNMT1 and EZH2 in cancer (Croonquist and Van Ness, 2005; Foran et al., 2010) . Interestingly, IL-6-dependent miRNAs that regulate DNMT1 gene expression levels in malignant cholangiocytes have recently been identified (Braconi et al., 2010) . Therefore, regulation of miRNAs may represent a mechanism by which IL-6 induces the expression of DNMT1. Conversely, epigenetic modifications such as DNA methylation are excellent biological candidates for the molecular arbitration of the immune-dysfunction phenotype associated with anxiety. DNA methylation can target genes for transcriptional silencing (Baylin, 2005) and is heavily influenced by environmental triggers such as diet, smoking and traumatic life events (Uddin et al., 2010; Nandakumar et al., 2011; Scoccianti et al., 2011) . In this way aberrant DNA methylation is a hallmark of a number of human diseases (Robertson, 2005) . Recently, immune-related genes were identified as targets of aberrant DNA methylation in post-traumatic stress disorder, supporting the hypothesis that DNA methylation contributes to the biology of anxiety-related disorders (Uddin et al., 2010) .
Given the importance that epigenetic regulatory genes have in the establishment and maintenance of DNA methylation patterns, it is likely that changes in their expression contribute to the molecular aetiology of neuropsychiatric disorders including anxiety. Moreover, altered epigenetic regulatory gene expression has been observed in patients with neuropsychiatric disorders (depression and schizophrenia) and has been found to be associated with increased anxiety levels in a mouse model of Rett syndrome (Poulter et al., 2008; Adachi et al., 2009; Zhubi et al., 2009) . However, the relationship between the cytokines expressed, such as IL-6, in response to anxiety and DNMTs/EZH2 expression and global DNA methylation has not previously been investigated. Thus, we profiled (i) the mRNA expression levels of DNMT1, DNMT3A, DNMT3B, DNMT3L and EZH2, and (ii) the global methylation changes in a cohort of anxious and nonanxious individuals and associated the findings with the mRNA and protein serum IL-6 levels in our patient cohorts.
Methods

Clinical sample collection
Participants were selected from an anxiety cohort described previously (O'Donovan et al., 2010) . Briefly, participants experiencing high or low levels of psychological distress were recruited from a large suburban area in Dublin, Ireland. The sample cohort included 27 participants with Hospital Anxiety and Depression Scale-Anxiety (HADS-A) scores in the clinical range (Zigmond and Snaith, 1983; Bjelland et al., 2002 ; anxious group, scores > 8) and 29 age-matched participants with low scores on the HADS-A (nonanxious group, scores < 8). Exclusion criteria were chronic illness, current or acute illness within the previous 2 weeks, alcoholism, use of medication, anaesthesia in the previous 3 months and night shift work in the previous 2 weeks. The HADS measure (a widely used and well-validated measure of nonsomatic symptoms of anxiety and depression) and the self-reported physical health measures used in this study have been described in detail previously (O'Donovan et al., 2010) . HADS-D scores and serum IL-6 levels had been previously measured for each participant (O'Donovan et al., 2010) . Blood samples were collected between 7:30 and 9:30 a.m. Participants fasted and abstained from smoking and caffeine from midnight, and avoided alcohol and exercise for 24 h before their appointment. The study was approved by the Vincent's Healthcare Group Ethics and Medical Research Committee.
Clinical biological sample collection
Twenty-five participants with HADS-A scores in the clinical range (anxious group) and 22 participants with low HADS-A scores (nonanxious group) had DNA/RNA of sufficient quantity and quality to carry out gene expression and global methylation analyses. Participants' blood samples (15 ml) were collected in sterile heparinized tubes and processed immediately. Whole-blood was overlaid onto a Ficoll-Paque layer and centrifuged for 30 min at 400g. Peripheral blood mononuclear cells (PBMCs) were removed from the interface, stained using trypan blue and counted using a haemocytometer. Cells were subsequently transferred into liquid nitrogen for long-term storage. Genomic DNA and total RNA were extracted from the PBMCs using an AllPrep DNA/RNA Mini Kit (Qiagen Ltd, West Sussex, UK). Concentration (absorbance at 260 nm) and purity (ratio of absorbance at 260 nm to absorbance at 280 nm) of the DNA and RNA were measured using a NanoDrop spectrophotometer (NanoDrop Technologies Inc., Delaware, Texas, USA). DNA and RNA samples with an A260 : A280 ratio between 1.7 and 2.0, and 1.9 and 2.1, respectively, were selected for methylation and expression analyses.
Gene selection DNMT1, DNMT3A, DNMT3B, DMNT3L and EZH2 were chosen on the basis of the following criteria: (i) their known epigenetic regulation functionality (defined by the Gene-Ontology database, http://www.geneontology.org/),
(ii) evidence of their altered expression in anxiety or other associated psychiatric disorders (Poulter et al., 2008; Zhubi et al., 2009 ) and (iii) evidence of their direct/ indirect regulation by IL-6 in inflammation-related diseases (Croonquist and Van Ness, 2005; Foran et al., 2010) . In addition, IL-6 mRNA expression was also determined.
Gene expression analysis
Differential gene expression between anxious and nonanxious individuals was determined by quantitative realtime PCR using the comparative C T method. All reagents were supplied by Applied Biosystems (Carlsbad, California, USA) unless otherwise stated. cDNAs were synthesized from total RNA (120 ng) using the HighCapacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, California, USA). Custom-made TaqMan 96-well array plates containing six predesigned inventoried TaqMan assays (DNMT1: Hs00154749_m1, DNMT3A: Hs01027166_m1, DNMT3B: Hs00171876_m1, DNMT3L: Hs01081364_m1, EZH2: Hs01016789_m1, IL-6: Hs00985639_m1) and an endogenous control gene (ACTB: Hs99999903_m1) were used. Quantitative realtime PCR assays consisted of cDNA (4 ng) and the 2XTaqMan Universal PCR master mix, and they were performed in triplicate under standard real-time cycling conditions on a 7500HT real-time PCR. Gene expression analysis was carried out on SDS 7500 softwareV2.0 (Applied Biosystems, Carlsbad, California, USA). The levels of target gene expression in participant samples were calculated using the ΔC T method (normalized to the endogenous control gene, ACTB), and target fold change, relative to a calibrator (average C T value of the nonanxious group), was used to generate relative quantification (RQ) values.
Global DNA methylation quantification in participant peripheral blood mononuclear cells
Global DNA methylation quantification was performed as per the manufacturer's instructions using the Methylflash Methylated DNA Quantification Kit (Epigentek, Farmingdale, New York, USA). Briefly, methylated DNA was detected using capture and detection antibodies to 5-mC and then quantified colorimetrically by reading the absorbance at 450 nm using a Multiskan-EX Microplate Photometer (Thermofisher Scientific Inc., Waltham, Massachusetts, USA). The absolute amount of methylated DNA (proportional to the optical density intensity) was measured and was quantified using a standard curve plotting the optical density values versus five serial dilutions of control methylated DNA (0.5-10 ng).
Statistical analyses
A sample size of 52 has 80% power to detect significant changes in global DNA methylation and gene expression, which have a large effect size (d = 0.8, α = 0.05). This study may be underpowered to detect significant small-medium changes in global DNA methylation and gene expression between the two groups. Power calculations were performed using G*Power version 3.1 (Faul et al., 2007) . A nonparametric Mann-Whitney U-test was performed to calculate the differences in mean ΔC T values, global DNA methylation levels (5-mC%) and age in anxious versus nonanxious participants. Pearson's χ 2 -test was used to compare frequencies of men, women and smokers among anxious individuals and controls. Spearman's rank-correlation was used to assess relationships between continuous variables. Multiple regression analysis was used to control for potential confounders and to explore the relationship between variables associated with HADS-A scores in anxious participants and IL-6 mRNA levels. Logistic regression analysis was carried out to evaluate whether global DNA methylation levels predicted anxiety status, correcting for potential confounders.
False discovery rate-adjusted P-values (P adjusted ) were calculated as described previously (Hochberg and Benjamini, 1990) and are listed together with the unadjusted P-values. Statistical analyses were carried out using SPSS (PASW statistics 18, Chicago, Illinois, USA). For all tests, significance was ascribed at P less than 0.05.
Results
Clinical and psychological features of the study population
The mean age of the anxious (n = 25) and nonanxious (n = 22) groups used in the current study did not differ significantly (mean = 33.04 years vs. mean = 32.73 years, respectively; Z = − 0.771, P = 0.441). The anxious cohort included 17 women and eight men. The nonanxious cohort included 14 women and eight men (Pearson's χ 2 = 0.99, d.f. = 1, P = 0.753). The mean HADS-A score of the anxious and nonanxious cohorts was 9.92 (HADS-A score range: 8-15) and 5 (HADS-A score range: 2-7, P < 0.0001), respectively. The frequency of smokers in the anxious group was significantly higher (6/25) than in the nonanxious group (0/22; Pearson's χ 2 = 5.38, d.f. = 1, P = 0.01). The groups did not differ significantly with respect to HADS-D scores (Z = − 1.301, P = 0.193).
DNMTs and EZH2 mRNA levels in anxious versus nonanxious individuals
There was no statistically significant difference in the mean levels of DNMTs, EZH2 and IL-6 gene expression (mean ΔC T values) between anxious individuals and controls (Mann-Whitney U-test; P = 0.93, 0.4, 0.39, 0.32, 0.76, respectively). DNMT3L was undetectable in all samples analysed.
Interestingly, IL-6 mRNA levels (logRQ values) were positively correlated with the HADS-A score in anxious participants (r = 0.44, P = 0.03, P adjusted = 0.08; Fig. 1a ). This trend was not observed in the nonanxious controls (P = 0.1). Similarly, DNMT1/3A and EZH2 mRNA levels (logRQ values) were correlated significantly with the HADS-A score among anxious participants only (r = 0.48, P = 0.018, P adjusted = 0.07; r = 0.56, P = 0.005, P adjusted = 0.025; r = 0.42, P = 0.04, P adjusted = 0.08, respectively; Fig. 1b-d ).
Multiple regression analysis was used to examine a prediction model of HADS-A scores in anxious participants only. The model, which included logRQ values for DNMT1, DNMT3A, DNMT3B and EZH2 as independent variables and controlled for potential confounders (age, sex, HADS-D scores, smoking and total cell count), was a significant predictor of HADS-A scores in the anxious cohort (F = 8.464, d.f. = 9, P = 0.001). This model explained 76.8% (adjusted R 2 = 0.768) of the variance in the HADS-A scores in the anxious group. However, mRNA expression of DNMT1, DNMT3A/3B and EZH2 in PBMCs was highly correlated in our cohort (Supplementary Figure 1, Correlation of mRNA expression levels of DNMT1/3A/3B and EZH2 with IL-6 mRNA Spearman's rank-correlation analysis demonstrated a significant positive correlation between the gene expressions of DNMT1/3A/3B/EZH2 and IL-6 (DNMT1: r = 0.56, P ≤ 0.001, P adjusted ≤ 0.002; DNMT3A: r = 0.55, P ≤ 0.001, P adjusted ≤ 0.002; DNMT3B: r = 0.33, P = 0.03, P adjusted = 0.03, EZH2: r = 0.55, P ≤ 0.001, P adjusted ≤ 0.002; Fig. 2 ). Multiple regression analysis revealed that DNMT1, DNMT3A and DNMT3B were significantly associated with IL-6 gene expression (P < 0.001, < 0.001, = 0.002, respectively), controlling for age, sex and total cell count (Supplementary Table 2 , Supplemental digital content 3, http://links.lww.com/PG/A118). In the anxious participants, an increase in the logRQ value of DNMT1, DNMT3A and DNMT3B by 1 SD (0.58, 0.35 and 0.47, respectively) coincided with an increase in the IL-6 logRQ value by 0.44, 0.39 and 0.27, respectively. In this study, we found no significant correlation between DNMT1, DNMT3A/3B, EZH2 and IL-6 mRNA expression in PBMCs and protein IL-6 levels in the serum (data not shown).
Global methylation (5-mC%) quantification in anxious versus nonanxious controls
Global methylation (5-mC%) analyses showed that anxious participants had significantly higher levels of global DNA methylation compared with controls (median 5-mC% SD: patients, 0.74 0.25; controls, 0.42 0.21; Z = − 3.197, P = 0.001, Mann-Whitney test; Fig. 3 ). Controlling for potential confounders (age, sex, total cell number, HADS-D scores and smoking), global 5-mC% was found to be significantly associated with anxiety (odds ratio = 48.5; 95% confidence interval, 1-2537.1; P = 0.05). In contrast, a negative correlation between 5-mC% and expression of DMNT1, DNMT3A, DNMT3B and EZH2 was observed (r = − 0.31, P = 0.055, P adjusted = 0.275; r = − 0.50, P = 0.001, P adjusted = 0.005; r = − 0.43, P = 0.007, P adjusted = 0.035; r = − 0.52, P = 0.001, P adjusted = 0.005, respectively). Thus, increased global 5-mC levels are associated with reduced expression of the epigenetic regulatory genes. No significant correlation between 5-mC levels and PBMC mRNA and protein serum IL-6 levels was observed in our cohort (r = − 0.18, P = 0.26; r = − 0.125, P = 0.46, respectively).
Discussion
We have, for the first time, identified differential global DNA methylation levels in PBMCs between anxious and nonanxious individuals. We also found that IL-6 gene expression in PBMCs correlates strongly with DNMTs/ EZH2 expression in anxious individuals and that the expression of these genes increases with increasing HADS-A scores in the anxious cohort.
In this study, we examined mRNA expression of DNMT1, DNMT3A, DNMT3B, DNMT3L, EZH2 and IL-6 genes in cohorts of anxious (n = 25) and nonanxious (n = 22) individuals and found no statistical difference in the mean gene expression (ΔC T ) levels between the two groups. DNMT3L was undetectable in all samples analysed. Previously, DNMT3L was found not to be expressed in peripheral blood leucocytes in a small cohort of individuals (n = 5; Minami et al., 2010) , and our results confirm this finding. Intriguingly, in the anxious cohort, DNMT1, DMNT3A, EZH2 and IL-6 expression increased with increasing anxiety severity scores on the HADS-A. After adjustment for multiple testing only DNMT3A remained significantly correlated with HADS-A scores in the anxious cohort. This trend was not observed in the nonanxious group, which had low scores on the HADS-A. A model including the expression levels of all epigenetic regulatory genes and controlling for potential confounders was a significant predictor of HADS-A scores in anxious participants, suggesting a synergistic effect of the epigenetic regulatory genes on HADS-A scores in anxious individuals. As the expression of our genes was highly correlated in our cohort (a finding supported by previous studies that have also shown highly correlated expression of these enzymes; Robertson et al., 1999; Balada et al., 2008) , the contribution of each gene to the prediction model could not be accurately accessed. These results warrant future investigation in a larger cohort of anxious individuals.
Interestingly, we found a significant correlation between the expression of DNMTs and EZH2 and IL-6 mRNA levels. These findings support previous studies that have demonstrated a link between DNMT1/EZH2 and IL-6 in human disease (Croonquist and Van Ness, 2005; Foran et al., 2010) , and highlight a potential relationship between inflammatory cytokines and important epigenetic regulatory enzymes in anxiety. This relationship supports a biological embedding model of stress (Miller et al., 2011) , whereby inflammatory cytokines interact (directly or indirectly) with epigenetic enzymes, potentially resulting in the alteration of an individual's methylome in a way that contributes to and perhaps exacerbates both the anxiety and the associated inflammation phenotypes.
In this study, we found no association between IL-6 mRNA and protein IL-6 levels in the serum. These findings are similar to those of a previous study of obese individuals, in which IL-6 mRNA levels in PBMCs did not reflect serum IL-6 protein levels (O'Rourke et al., 2006) . This could be a result of post-transcriptional regulation of IL-6 expression and/or the presence of IL-6 in the serum from sources other than PBMCs (e.g. liver and adipose tissue; O' Rourke et al., 2006) .
Examination of global methylation (5-mC%) levels indicated that anxious individuals had significantly higher levels of 5-mC compared with nonanxious controls, suggesting that anxious individuals have global hypermethylation of their genome. Moreover, our findings suggest that aberrant DNA methylation patterns in anxious individuals can be identified by examining methylation profiles in peripheral blood. A recent intraindividual cross-tissue study suggested that some interindividual epigenetic variation may be correlated between the blood and the brain, demonstrating that blood may act as a proxy in studies of certain neurobiological phenotypes (Davies et al., 2012) . Moreover, studies analysing global methylation in a number of cancers have proposed that examination of the 5-mC content in blood could act as a reliable biomarker of certain cancers (Woo and Kim, 2012) ; thus, global hypermethylation (as assessed by 5-mC %) may represent a novel biomarker of anxiety. Blood 5-mC % levels observed in this study ( < 1.5%) are consistent with those in previous studies by our group and others examining 5-mC content using an antibody to 5-mC in blood and various other tissues (Kinney and Pradhan, 2011; Nestor et al., 2012; Woo and Kim, 2012; Murphy et al., 2013) .
DNMT and EZH2 gene expression levels were inversely correlated with global methylation levels. Although paradoxical, these findings are in line with those of Nonanxious Anxious r =0.532 P ≤0.001
Relationship between epigenetic regulatory genes and IL-6 gene expression. Scatter plot illustrating correlation between DNMT1, DNMT3A, DNMT3B and EZH2 gene expression levels and IL-6 gene expression levels. The correlation was assessed using Spearman's rank-correlation analysis. DNMT, DNA methyltransferase; EZH2, Enhancer of Zeste Homolog 2; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; IL-6, interleukin-6; RQ, relative quantification.
previous studies. An inverse correlation between DNMT1 and DNMT3A/3B gene expression and global methylation levels was found in patients with lupus (Balada et al., 2008; Liu et al., 2011) . In mice, DNA methylation appears to act as a feedback regulation mechanism of DNMT1 gene expression (Slack et al., 1999) . If a similar process occurs in humans, it could provide an explanation for the inverse correlation found in this study. Expression of DNMT1/3B is, however, associated with increased promoter hypermethylation of specific genes in both cancer and suicidal depression (Poulter et al., 2008; Foran et al., 2010) . Therefore, future studies examining the association between DNMT expression and promoter hypermethylation of important neurobiological and immunological genes that may play an important role in anxiety could yield important findings.
A limitation of the current study is that the cross-sectional design does not allow us to determine the direction of the relationship observed between anxiety, IL-6 and epigenetic regulatory gene expression, and DNA methylation changes. However, Foran et al. (2010) have shown that treatment of colon cancer cells with IL-6 resulted in an increase in DNMT1 expression and promoter hypermethylation of specific genes. Hence, it is likely that in severely anxious individuals increased IL-6 gene expression (perhaps through IL-6-dependent expression of miRNAs) increases expression of the DNMTs/EZH2 genes, and this may lead to aberrant regulation of locusspecific DNA methylation profiles.
In conclusion, this study, although preliminary, provides novel insights into the relationship between anxiety, epigenetics and the inflammatory cytokine IL-6, and provides a basis for future epigenetic studies examining gene-specific methylation changes. Moreover, individuals with severe anxiety, elevated IL-6 levels and aberrant DNMT/EZH2 expression may be candidates for treatment with anti-IL-6 drugs or cognitive behavioural therapy (also shown to reduce proinflammatory signalling, Antoni et al., 2012) . Decreasing IL-6 levels in these individuals may modify epigenetic mechanisms, potentially reducing their risk for developing inflammationrelated diseases in the future.
